What Is Retatrutide? An Explanation of the Triple Agonist

In brief. Retatrutide, development code LY3437943, is a synthetic peptide that acts as an agonist for three receptors: GIP, GLP-1, and glucagon. This triple action distinguishes it from tirzepatide, which targets two of these receptors, and from semaglutide, which targets only one. It is currently in clinical development and has not been approved by any health authority.

What is retatrutide?

Retatrutide is a peptide analog developed by Eli Lilly under the code LY3437943. Its unique feature lies in its pharmacological profile: it binds to and activates three distinct receptors involved in energy metabolism.

• The GIP receptor (glucose-dependent insulinotropic polypeptide)
• The GLP-1 receptor (glucagon-like peptide-1)
• The glucagon receptor

Structurally, it is a peptide consisting of about 30 amino acids built on a backbone derived from GIP, carrying a fatty acid chain. This acylation allows it to bind to plasma albumin, which slows its elimination and explains the weekly dosing schedule used in clinical trials.

How does triple agonism make a difference?

The three receptors do not perform the same function, and that is the whole point of the combination.

The first two reduce energy intake. The third acts on energy expenditure. This is the reasoning that led to the addition of the glucagon component: acting on both sides of the energy balance rather than just one.

Glucagon receptor agonism is also what makes the molecule challenging. Activating glucagon in isolation raises blood glucose levels, which is precisely what we seek to avoid in a diabetic patient. Striking the right balance among these three actions is therefore at the heart of the design challenge.

What do the published clinical trials report?

Two Phase 2 trials were published in 2023, and they constitute the bulk of the available literature on this compound.

Obesity, New England Journal of Medicine, June 2023. A randomized Phase 2 trial involving 338 adults, conducted over 48 weeks. At the highest dose evaluated, 12 mg per week, the reported mean reduction in body weight was 24.2% at week 48. The most common adverse effects were gastrointestinal, primarily nausea, diarrhea, and vomiting, mostly mild to moderate in severity and concentrated during the dose-escalation phase.

Type 2 Diabetes, The Lancet, 2023. A 36-week Phase 2 trial reporting reductions in glycated hemoglobin and body weight in a population of patients with type 2 diabetes.

A Phase 3 program, TRIUMPH, is currently underway. To date, retatrutide has not received marketing authorization from the FDA, the EMA, or the ANSM. The figures above describe what the published scientific literature reports about a compound in development—nothing more.

Retatrutide, tirzepatide, semaglutide: what’s the difference?

This is the most frequently asked question, and it can be summarized in a table.

This table does not compare drugs within the same trial. These are three separate studies, with different populations, durations, and protocols. A direct comparison of the percentages is methodologically flawed. Only a head-to-head comparative trial would allow for a conclusion, and none currently exists.

What the table does show, however, is a trend: in published trials, the addition of receptor targets is associated with more pronounced weight loss, at the cost of an adverse effect profile that requires monitoring.

How is retatrutide handled in the laboratory?

Like all acylated peptide analogs, it is delivered lyophilized and must be reconstituted before any experimental work. Three specific points:

• The fatty acid chain makes the molecule sensitive to mechanical agitation. The vial should be gently rotated; it should never be shaken.
• Once reconstituted, the solution should be stored between 2 and 8 °C, protected from light, and its stability is measured in weeks, not months.
• Repeated freeze-thaw cycles degrade the molecule. It is better to aliquot the solution than to refreeze it.

Detailed instructions can be found in our guide to reconstituting a lyophilized peptide, and the reconstitution calculator provides the solvent volume required for the target concentration.

How do you verify the quality of a retatrutide batch?

An acylated analog is more difficult to synthesize cleanly than a short peptide: coupling impurities and improperly acylated forms are common. Three pieces of information to request on the batch certificate of analysis:

• HPLC purity with the chromatogram, not just a reported number
• Identity confirmed by mass spectrometry, measured mass compared to the theoretical mass
• Net peptide content, which is not the same as purity and determines the actual concentration of your solution

Our guide How to Read a Certificate of Analysis explains each section in detail. Our batch reports are publicly available on the Certificates of Analysis page.

View the compound’s product page: Retatrutide 10 mg. Other metabolic compounds in the catalog are available in the store.